BRAF and non-small cell lung carcinoma: BRAF mutations, present in approximately 2% of NSCLC cases, with p.V600E being the most common type, have shown clinical efficacy with ICIs in two retrospective cohorts of 39 and 38 patients, including those with p.V600E variants.